Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaclotide in IBS-C
NCT01880424Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2013
- Primary completion
- May 2015
- Modality
- Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Linaclotide with Placebo (2 arms). Primary endpoints: 12-week Abdominal Pain/Abdominal Discomfort Weekly Responder and 12-week Irritable Bowel Syndrome (IBS) Degree of Relief Responder. Started Jul 2013; status: completed.
02
Drugs
linaclotide
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT01880424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01880424.